NCT00712283View on ClinicalTrials.gov

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions

Healthy

Interventions

DRUG

Neramexane mesylate

tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days

Trial Locations (1)

60318

Merz Pharmaceuticals, Frankfurt am Main